HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

Introduction: Navigating the Complexity of Biliary Tract Cancers

Biliary tract cancers (BTCs), a heterogeneous group of malignancies including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder cancer (GBC), have long been associated with a dismal prognosis. For years, the therapeutic landscape was stagnant, relying heavily on cytotoxic chemotherapy regimens like gemcitabine and cisplatin. While the integration of immunotherapy has recently improved first-line outcomes, the five-year survival rate for advanced disease remains stubbornly low.

In the era of precision oncology, the identification of actionable molecular drivers has become the cornerstone of drug development. Among these, the human epidermal growth factor receptor 2 (HER2/ERBB2) has emerged as a promising target. Historically celebrated in breast and gastric cancers, HER2 alterations are now being scrutinized in BTC. However, until recently, large-scale, multi-institutional data clarifying the prognostic weight of HER2 and the real-world impact of targeted interventions in BTC were lacking.

A landmark study published in Clinical Cancer Research, titled “HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional Analysis,” provides much-needed clarity. By aggregating data from two global oncology leaders—Yonsei Cancer Center in South Korea and MD Anderson Cancer Center in the United States—researchers have mapped the clinical and genomic landscape of HER2 in advanced BTC.

Highlights of the Study

The study presents several critical insights for clinicians and researchers:

1. HER2-positivity is prevalent in approximately 25% of advanced BTC cases, particularly in gallbladder cancer and extrahepatic cholangiocarcinoma.
2. HER2 status serves as a negative prognostic indicator, with HER2-positive patients experiencing significantly shorter progression-free survival (PFS) and overall survival (OS) when treated with standard therapies.
3. The use of anti-HER2 targeted therapy dramatically improves survival outcomes, more than doubling the median OS compared to HER2-positive patients who do not receive targeted treatment.
4. Genomic profiling reveals distinct molecular co-alterations, with HER2-positive tumors showing an enrichment in angiogenesis pathways, while HER2-negative tumors are more frequently driven by KRAS mutations.

Study Design and Definition of HER2-Positivity

This retrospective analysis included a comprehensive cohort of 388 patients with advanced BTCs treated between 2009 and 2023. The multi-institutional nature of the study ensures that the findings are applicable across different ethnic populations and clinical settings.

Defining HER2 Status

One of the primary challenges in HER2 research in BTC has been the lack of standardized diagnostic criteria. In this study, HER2-positivity was strictly defined using an integrated approach:
– Immunohistochemistry (IHC) score of 3+.
– IHC score of 2+ combined with positive in situ hybridization (ISH).
– ERBB2 amplification detected via next-generation sequencing (NGS).

This multi-modal diagnostic framework reflects the evolving standards in precision medicine, ensuring that patients who might benefit from targeted therapy are accurately identified.

Key Findings: The Prognostic Impact of HER2

In the epidemiology analysis cohort (n=309), the prevalence of HER2-positivity was 25.2%. This high frequency underscores the importance of routine molecular screening for this population. However, the survival analysis revealed a sobering reality: HER2-positivity is associated with more aggressive disease biology.

Survival Disparities

When comparing HER2-positive patients to their HER2-negative counterparts, the researchers noted a clear survival disadvantage. The median overall survival (OS) for HER2-positive patients was 13.7 months, compared to 17.1 months for HER2-negative patients (Hazard Ratio [HR], 1.25; 95% CI, 0.97-1.60).

More strikingly, the impact on first-line progression-free survival (PFS) was highly significant. HER2-positive patients had a median PFS of only 5.1 months, whereas HER2-negative patients reached 7.4 months (HR, 1.91; 95% CI, 1.46-2.48). This indicates that standard-of-care chemotherapy may be less effective in HER2-amplified tumors, highlighting a critical unmet need for alternative first-line strategies.

The Therapeutic Breakthrough: Impact of Anti-HER2 Intervention

While HER2-positivity denotes a poorer prognosis under standard care, it simultaneously opens a door to highly effective targeted treatments. The study analyzed the outcomes of patients who received anti-HER2 therapies (such as trastuzumab, pertuzumab, or antibody-drug conjugates) versus those who did not.

In the HER2-positive subgroup, those treated with anti-HER2 therapy achieved a median OS of 18.2 months. In contrast, those who did not receive targeted therapy had a median OS of only 8.1 months. This represents a staggering reduction in the risk of death (HR, 0.39; 95% CI, 0.21-0.62).

These findings suggest that while HER2-positivity identifies a high-risk group, the administration of targeted therapy can effectively mitigate this risk, potentially transforming a poor prognosis into a manageable chronic condition.

Genomic Landscape and Pathway Enrichment

To understand the biological drivers behind these clinical observations, the researchers conducted an integrated genomic analysis. They discovered that HER2-positive and HER2-negative BTCs are molecularly distinct entities.

Angiogenesis and KRAS Divergence

HER2-positive BTCs showed the strongest enrichment in angiogenesis pathway alterations. This biological insight suggests that HER2-positive tumors may be more dependent on vascular proliferation, providing a rationale for investigating combination therapies that target both the HER2 receptor and the VEGF pathway.

Conversely, HER2-negative BTCs were characterized by a higher frequency of KRAS mutations. Since KRAS and HER2 alterations are often mutually exclusive in many solid tumors, this finding helps clinicians narrow down the primary oncogenic drivers in individual patients, further refining the selection of targeted agents.

Expert Commentary: Towards a New Standard of Care

The results of this multi-institutional analysis carry profound implications for clinical practice. The significant survival benefit observed with anti-HER2 therapy suggests that HER2 testing should no longer be considered optional in advanced BTC; it should be integrated into the initial diagnostic workup alongside MSI, NTRK, and FGFR2 testing.

Standardizing HER2 Testing

A major hurdle remains the standardization of IHC scoring for BTC. Unlike breast or gastric cancer, which have established guidelines (e.g., ASCO/CAP), BTC scoring has often been extrapolated from other tumor types. The researchers in this study call for the development of BTC-specific HER2 diagnostic criteria to ensure consistency across pathology labs globally.

Furthermore, the emergence of antibody-drug conjugates (ADCs) like Trastuzumab Deruxtecan (T-DXd) has changed the paradigm. These agents have shown efficacy even in “HER2-low” (IHC 1+ or 2+/ISH-) cases in other cancers. Future research must determine if the survival benefits seen in this study can be extended to the HER2-low population in BTC.

Conclusion: A Call for Action

HER2 is a clinically meaningful biomarker with both prognostic and predictive relevance in advanced biliary tract cancer. While it identifies a patient population with more aggressive disease and shorter survival on conventional therapy, it also defines a group that derives immense benefit from targeted intervention.

The study by Lee et al. provides a robust evidence base for the routine inclusion of HER2 testing in the management of BTC. By identifying these patients early, clinicians can move beyond the “one-size-fits-all” chemotherapy approach and offer personalized strategies that significantly extend life. As we await prospective clinical trial results for newer anti-HER2 agents, this multi-institutional analysis stands as a pivotal reference for the current standard of care.

Funding and Clinical Trials

This research was supported by grants from the National Research Foundation of Korea and institutional research funds from Yonsei University and MD Anderson Cancer Center. Relevant clinical trials investigating HER2 in BTC include studies involving zanidatamab (NCT04466891) and trastuzumab deruxtecan (NCT04482309).

References

1. Lee SS, Seo DH, Chung T, et al. HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional Analysis. Clin Cancer Res. 2025 Nov 14. doi: 10.1158/1078-0432.CCR-25-2153. PMID: 41235921.
2. Valle JW, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022.
3. Javle M, et al. HER2 / neu (ERBB2) expression and gene amplification in cholangiocarcinoma and gallbladder cancer. Cancer. 2014.